Key Highlights

  • Acrux (ASX:ACR) shares were up 10.00% at $0.011 during the 22 October 2026 session, while the S&P/ASX 200 was down 0.64%.
  • In its Quarterly Report dated 19 October 2026, Acrux said the FDA confirmed the Phase III pathway for its Female Testosterone MDTS for HSDD.
  • The company reported A$1.977 million of R&D tax incentive receipts and cash of A$1.396 million at 30 September 2026.

Acrux Limited (ASX:ACR) shares were up 10.00% at $0.011 during the Trading session on Thursday 22 October 2026. At 11:55 am, the S&P/ASX 200 stood at 8,774.90, down 0.64% (56.40 points), while the All Ordinaries stood at 8,897.80, down 0.66%. Acrux is a Melbourne-based specialty pharmaceutical company that develops and commercialises topically applied products, and it is now focused on a Female Testosterone metered-dose transdermal spray.

About the Company

Acrux Limited is a specialty pharma company listed on the ASX under the code ACR, with offices at 103-113 Stanley Street, West Melbourne, Victoria. Drawing on 25 years of experience, it has marketed a number of products worldwide through licensees, with an emphasis on the United States.

John Warmbrunn serves as CEO and Managing Director, and Joanna Johnson as CFO and Company Secretary. As a Pooled Development Fund, it may not borrow money except for short-term purposes.

Business Overview

Acrux has a track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Its commercialised Topical Generic Portfolio generates profit share and Royalty income from licensing in the United States, where licensee Tru Pharma reports sales of Nitroglycerine 0.4% Ointment and Dapsone 7.5% Gel.

The company's development focus is Female Testosterone MDTS for postmenopausal women with Hypoactive Sexual Desire Disorder (HSDD). It has also realigned its cost base towards that project, and all activities on the generic portfolio and external fee-for-service revenues have ceased.

FDA Confirms Phase III Pathway

In its quarterly activities report and Appendix 4C dated 19 October 2026, Acrux said the US Food and Drug Administration had confirmed the clinical Phase III regulatory pathway for Female Testosterone MDTS in HSDD. The company is finalising protocols for two 24-week trials to demonstrate reproducible efficacy, with an additional 28 weeks of data to inform safety for chronic treatment.

The FDA acknowledged the product as a new formulation and said a chronic dermal and systemic safety study would be consistent with its guidelines. Acrux said it will be eligible to apply for a three-year exclusivity period when it submits for approval, and that the agency's positions support co-development discussions with potential partners.

September Quarter Cash Flow

The Appendix 4C for the quarter ended 30 September 2026 shows net cash from Operating Activities of A$226,000, supported by receipt of the FY26 Research and Development Tax Incentive rebate of A$1.977 million. Receipts from customers were A$463,000, comprising profit share and royalty income and laboratory fee-for-service revenue. The narrative section of the report cites A$0.266 million for the same measure.

Advances of A$950,000 received in the prior financial year against the rebate were repaid in full, with interest of A$113,000. Cash and cash equivalents were A$1.396 million at quarter end, down from A$1.705 million.

Costs and Capital Raising

Operating expenditure for the quarter was A$1.527 million. Staff costs were A$1.344 million, including A$329,000 paid in connection with six redundancies actioned in July, which reduced headcount to 19. Administration and corporate costs were A$478,000. Research and development payments were A$255,000, and repayment of borrowings totalled A$1.008 million.

Acrux received A$575,000 for the second Tranche of a Placement announced on 11 May 2026 with binding commitments of A$1.6 million. It said it is working on several transactions to ensure capital is available to progress the clinical development program.

Related Sector Context

Clinical-stage and specialty pharmaceutical companies on the ASX typically advance through regulatory discussions, trials and partnering,. Acrux cites a recent FDA public workshop that highlighted unmet need for an FDA-approved testosterone treatment with female-appropriate dosing.

At the time of the data, the S&P/ASX 200 was down 0.64% and the All Ordinaries down 0.66%, while Acrux shares were up 10.00%.

Risks to Weigh In

Female Testosterone MDTS has yet to complete Phase III trials, and regulatory approval is not assured. Acrux does not yet have a development partner confirmed, and discussions with potential partners continue.

Funding is a central uncertainty: the company reported cash and equivalents of A$1.396 million at quarter end and total available funding of A$1.795 million including unused facilities. The company has said it is working on several transactions to fund the clinical program.

Catalysts on Watch

Acrux is finalising the Phase III protocols for two 24-week efficacy trials and a longer safety component. Updates on co-development discussions, which the chief executive said are moving to the next level, are also anticipated.

The company is also working on capital transactions, and its next quarterly report will show how Cash Flow and expenditure develop as it concentrates its resources on the Female Testosterone project.

Putting It Together

Acrux shares were up 10.00% to $0.011 during the 22 October 2026 session as the benchmarks traded lower. The company's 19 October 2026 quarterly report set out FDA guidance on the Phase III pathway, a cash balance of A$1.396 million and ongoing work on funding.